(SLGL) Sol-Gel Technologies Ltd. Business Model Canvas Research

Sol-Gel Technologies Ltd. relies on manufacturing and formulation partners to scale topical creams that need tight quality control and repeatable microencapsulation. In 2025, the company reported $14.4 million in product revenue, so outside production support helps bridge clinical batches to commercial supply without heavy in-house capex.

• Scale-up for topical creams
• Quality control and batch consistency
• Supports commercial supply buildout

Sol-Gel Technologies Ltd. uses generic dermatology collaborators to source, develop, and commercialize topical drug copies, so the company is not tied only to proprietary assets. This widens its partner base and lowers reliance on any single product line.

• Sources active ingredient and supply partners
• Shares development and filing work
• Uses commercialization partners for launch

Sol-Gel Technologies Ltd. must keep a tight regulatory filing stack: trial data, safety reviews, CMC (chemistry, manufacturing, and controls) files, and label-ready dossiers for FDA and other agencies. This matters for both proprietary and generic products, since market access depends on approved documentation and compliant manufacturing.

• Prepare approval dossiers and safety packs
• Prove manufacturing and quality compliance
• Support both proprietary and generic filings
• Track agency feedback to speed access

Sol-Gel Technologies Ltd. uses commercial transfer with Perrigo to move 2 FDA-approved skin assets, EPSOLAY and TWYNEO, from R&D into launch and sales. Perrigo handles the market-side push, so Sol-Gel’s work turns clinical output into revenue-bearing products.

• 2 approved assets moved to market
• Perrigo supports launch and sales
• Links R&D to commercialization

Founded in 1997, Sol-Gel Technologies Ltd. keeps its headquarters in Ness Ziona, Israel, where its local team anchors research, development, and day-to-day operations. This Israel-based core is the company’s key resource for managing its dermatology pipeline and execution.

• Founded: 1997
• HQ: Ness Ziona, Israel
• Core roles: R&D and operations

Sol-Gel Technologies Ltd. depends on patents, formulation know-how, and licensing rights to protect its dermatology pipeline and keep copycats out. Those rights also strengthen partner value with Perrigo, helping turn approved products into licensed sales, royalties, and shared commercial upside.

• Patents defend product exclusivity.
• Know-how protects formulation edge.
• Licenses support Perrigo partnerships.

Sol-Gel Technologies’ value is its broad dermatology pipeline: acne, rosacea, palmoplantar keratoderma, psoriasis, and other skin disorders. That 5-area spread lowers single-product risk and keeps the long-term upside open as each indication can add a new revenue stream.

• 5 dermatology targets
• Lower dependency on one drug
• More shots at approval

Sol-Gel Technologies Ltd. can use generic topical dermatology programs to sit beside its branded products, giving it a second revenue lane and broader payer reach. That matters because branded assets like TWYNEO and EPSOLAY target premium pricing, while generics compete on volume and can help smooth cash flow when launch timing or demand is uneven.

• Branded plus generic = wider market access
• Volume sales can offset launch risk
• More paths to dermatology revenue

Sol-Gel Technologies Ltd. keeps a tight link with investigators and study sites because clinical work depends on clear protocol guidance, clean data flow, and fast trial fixes. Even with 2 U.S.-approved dermatology products, the pipeline still needs active site support to protect speed and data quality.

• Protocol guidance keeps sites aligned

• Data coordination reduces trial delays

• Trial support lifts execution quality

Sol-Gel Technologies Ltd. needs steady regulatory and payer dialogue because dermatology drugs still need coverage, prior auth, and label-fit to turn approvals into use. With 2 FDA-approved products, the company must back each launch with clean evidence packages and aligned labeling so payers can justify reimbursement.

• 2 FDA-approved dermatology products
• Evidence supports payer access
• Label alignment speeds reimbursement

Sol-Gel Technologies Ltd. uses licensing and partnering to turn its dermatology assets into cash without building a large sales team, which fits a small clinical-stage pharma model. This matters because partners can fund development and speed access to markets; Sol-Gel’s licensed products, TWYNEO and EPSOLAY, show how out-licensing can scale reach faster than direct sales.

• Monetizes assets beyond direct sales
• Fits a capital-light clinical-stage model
• Partners expand market reach faster

Sol-Gel Technologies Ltd. uses company updates, partner decks, and medical documents to keep investors, prescribers, and collaborators aligned on pipeline and product data. The Company has 2 FDA-approved dermatology products, Twyneo and Epsolay, so these channels are key for launch progress, label facts, and development status.

• Supports investor due diligence
• Trains prescribers on product use
• Shares pipeline and partner updates

Psoriasis patients are a large chronic dermatology group, with about 125 million people affected worldwide and a U.S. prevalence near 3%. For Sol-Gel Technologies Ltd., this segment fits its psoriasis work on erlotinib, tapinarof, and roflumilast, and it can also broaden into other inflammatory skin uses as the pipeline grows.

• Large, recurring treatment need
• Strong fit for pipeline expansion

Sol-Gel Technologies Ltd. also serves generic topical dermatology buyers, mainly pharmacies, healthcare systems, and distribution partners. This matters because generics drive scale: in the U.S., generic drugs fill about 90% of prescriptions but account for only about 18% of drug spending, so this segment can widen reach and reduce dependence on branded products.

• Pharmacies: high-volume replenishment
• Health systems: formulary-driven demand
• Distributors: wider channel access
• Diversifies beyond branded innovation

Sol-Gel Technologies Ltd. must fund topical-cream manufacturing, batch validation, and tight supply-chain control; the jump from clinical to commercial scale usually raises COGS and working capital right before launch. That makes scale-up one of the most capital-heavy steps in the model.

• Production lines and QA must be ready early.
• Scale-up risk rises near first launch.
• Supplier control protects yield and timing.

Sol-Gel Technologies Ltd. still carries corporate overhead even as a clinical-stage company: headquarters in Israel, public-company admin, and Perrigo partnership work all flow through SG&A. The mix is small in absolute terms but it matters, because every commercial step for Twyneo and Epsolay adds coordination, legal, and supply-chain cost.

• Israel HQ and public-company overhead
• Perrigo collaboration adds coordination cost

Generic topical dermatology products can add non-branded, repeatable income for Sol-Gel Technologies Ltd. This stream usually starts after development and approval, then broadens the mix beyond pipeline risk; in the latest filings I can verify, Sol-Gel still had limited scale, so even small generic launches could lift diversification and cash flow.

• Non-branded sales add extra revenue
• Launch follows development and approval
• Broadens product and payer mix

Sol-Gel Technologies Ltd can monetize assets outside direct sales through upfront fees and joint-development payments, a fit for its pipeline-led biotech model. In FY2025, this matters because the company had no broad product revenue base, so collaboration cash can help fund development and reduce dilution pressure.

• Upfront fees can fund trials
• Joint work can share risk
• Out-licensing adds non-dilutive cash